Industry donated $4.38 bil. worth of medicine and assistance to support healthcare in developing countries over five years, according to a report issued by the International Federation of Pharmaceutical Manufacturers & Associations in December. Over that time, pharma donated health interventions to help as many as 539 mil. people through 126 health partnerships. In a formal validation report on IFPMA's survey, the London School of Economics said that IFPMA's estimate of pharma philanthropy is likely undervalued...
You may also be interested in...
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.